Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $12.2308.

Several analysts have recently weighed in on CMPX shares. Citizens Jmp assumed coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price objective for the company. JMP Securities set a $10.00 price target on Compass Therapeutics in a report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. William Blair started coverage on Compass Therapeutics in a research note on Monday, January 5th. They issued an “outperform” rating for the company. Finally, Lifesci Capital started coverage on Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 price target for the company.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $6.52 on Tuesday. The firm has a market capitalization of $1.16 billion, a P/E ratio of -14.49 and a beta of 1.46. The stock has a fifty day moving average price of $5.49 and a two-hundred day moving average price of $4.30. Compass Therapeutics has a 52-week low of $1.33 and a 52-week high of $6.71.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. On average, equities research analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its position in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares during the last quarter. Creative Planning bought a new position in Compass Therapeutics in the 2nd quarter valued at $30,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Compass Therapeutics in the 4th quarter valued at $32,000. Strs Ohio bought a new stake in shares of Compass Therapeutics during the first quarter worth $34,000. Finally, Apollon Wealth Management LLC acquired a new position in shares of Compass Therapeutics during the third quarter valued at $35,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.